AngioDynamics (NASDAQ:ANGO) Shares Pass Above Two Hundred Day Moving Average of $21.46

AngioDynamics, Inc. (NASDAQ:ANGOGet Rating) shares passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $21.46 and traded as high as $21.52. AngioDynamics shares last traded at $20.79, with a volume of 107,246 shares changing hands.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. TheStreet lowered shares of AngioDynamics from a “c-” rating to a “d+” rating in a research report on Friday, July 8th. Raymond James reduced their price objective on shares of AngioDynamics from $32.00 to $27.00 and set a “strong-buy” rating for the company in a research report on Wednesday, July 13th. Finally, Canaccord Genuity Group reduced their price objective on shares of AngioDynamics from $40.00 to $35.00 in a research report on Wednesday, July 13th.

AngioDynamics Stock Down 1.6 %

The business’s 50-day moving average price is $22.46 and its 200-day moving average price is $21.44. The company has a quick ratio of 1.24, a current ratio of 1.93 and a debt-to-equity ratio of 0.06.

AngioDynamics (NASDAQ:ANGOGet Rating) last posted its quarterly earnings results on Tuesday, July 12th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.01. The business had revenue of $87.00 million during the quarter, compared to analyst estimates of $82.91 million. AngioDynamics had a negative net margin of 8.40% and a negative return on equity of 0.04%. AngioDynamics’s revenue for the quarter was up 13.3% compared to the same quarter last year. Sell-side analysts predict that AngioDynamics, Inc. will post 0.03 EPS for the current fiscal year.

Insider Transactions at AngioDynamics

In related news, SVP Dave Helsel sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $22.44, for a total transaction of $112,200.00. Following the transaction, the senior vice president now owns 23,822 shares of the company’s stock, valued at $534,565.68. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.80% of the stock is owned by insiders.

Hedge Funds Weigh In On AngioDynamics

A number of institutional investors have recently modified their holdings of ANGO. Legal & General Group Plc grew its stake in shares of AngioDynamics by 0.9% in the second quarter. Legal & General Group Plc now owns 93,102 shares of the medical instruments supplier’s stock worth $1,802,000 after acquiring an additional 851 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in shares of AngioDynamics by 20.9% in the second quarter. Thrivent Financial for Lutherans now owns 38,100 shares of the medical instruments supplier’s stock worth $737,000 after acquiring an additional 6,581 shares during the last quarter. Cubist Systematic Strategies LLC grew its stake in shares of AngioDynamics by 33.2% in the second quarter. Cubist Systematic Strategies LLC now owns 106,952 shares of the medical instruments supplier’s stock worth $2,070,000 after acquiring an additional 26,674 shares during the last quarter. Citadel Advisors LLC grew its stake in shares of AngioDynamics by 27.3% in the second quarter. Citadel Advisors LLC now owns 265,882 shares of the medical instruments supplier’s stock worth $5,145,000 after acquiring an additional 57,037 shares during the last quarter. Finally, UBS Asset Management Americas Inc. grew its stake in shares of AngioDynamics by 13.7% in the second quarter. UBS Asset Management Americas Inc. now owns 52,383 shares of the medical instruments supplier’s stock worth $1,014,000 after acquiring an additional 6,311 shares during the last quarter. Institutional investors own 96.13% of the company’s stock.

AngioDynamics Company Profile

(Get Rating)

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.

Recommended Stories

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.